0001209191-21-041107.txt : 20210616 0001209191-21-041107.hdr.sgml : 20210616 20210616191925 ACCESSION NUMBER: 0001209191-21-041107 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210616 FILED AS OF DATE: 20210616 DATE AS OF CHANGE: 20210616 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: NABEL ELIZABETH G CENTRAL INDEX KEY: 0001619929 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40502 FILM NUMBER: 211022856 MAIL ADDRESS: STREET 1: BRIGHAM AND WOMEN'S HOSPITAL STREET 2: 75 FRANCIS ST CITY: BOSTON STATE: MA ZIP: 02115 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lyell Immunopharma, Inc. CENTRAL INDEX KEY: 0001806952 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 833006753 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 EAST JAMIE COURT STREET 2: SUITE 301 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650 695-0677 MAIL ADDRESS: STREET 1: 400 EAST JAMIE COURT STREET 2: SUITE 301 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2021-06-16 0 0001806952 Lyell Immunopharma, Inc. LYEL 0001619929 NABEL ELIZABETH G C/O LYELL IMMUNOPHARMA, INC. 400 EAST JAMIE COURT, SUITE 301 SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Option (right to buy) 12.67 2031-04-21 Common Stock 400000 D The shares vest in equal monthly installments over the thirty-six months following April 22, 2021. The option provides for an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. /s/ Heather D. Turner, as Attorney-in-fact 2021-06-16 EX-24 2 attachment1.htm EX-24 DOCUMENT

POWER OF ATTORNEY
       Know all by these presents that the undersigned hereby constitutes and
appoints Heather Turner Charles Newton and Hector Casab of Lyell Immunopharma
Inc. and Lauren Creel and Allison Peth of Cooley LLP or any of them signing
singly with full power of substitution the undersigned's true and lawful
attorney in fact to:
(1)		execute for and on behalf of the undersigned in the undersigned's capacity
as an officer director or beneficial owner of more than 10% of a registered
class of securities of Lyell Immunopharma Inc. (the "Company") Forms 3 4 and 5
(including any amendments thereto) in accordance with Section 16(a) of the
Securities Exchange Act of 1934 as amended (the "Exchange Act") and the rules
thereunder and a Form ID Uniform Application for Access Codes to File on EDGAR;
(2)	do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to execute such Forms 3 4 or 5 or Form ID
(including any amendments thereto) and timely file such forms with the United
States Securities and Exchange Commission and any stock exchange or similar
authority; and
(3)	take any other action of any nature whatsoever in connection with the
foregoing which in the opinion of such attorney-in-fact may be of benefit in the
best interest of or legally required by the undersigned it being understood that
the documents executed by such attorney-in-fact on behalf of the undersigned
pursuant to this Power of Attorney shall be in such form and shall contain such
terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
       The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever requisite
necessary or proper to be done in the exercise of any of the rights and powers
herein granted as fully to all intents and purposes as the undersigned might or
could do if personally present with full power of substitution or revocation
hereby ratifying and confirming all that such attorney-in-fact or such
attorney-in-fact's substitute or substitutes shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted.  The undersigned acknowledges that the foregoing attorneys-in-fact in
serving in such capacity at the request of the undersigned are not assuming nor
is the Company assuming any of the undersigned's responsibilities to comply with
Section 16 of the Exchange Act.
       This Power of Attorney shall remain in full force and effect until the
earliest to occur of (a) the undersigned is no longer required to file Forms 3 4
and 5 with respect to the undersigned's holdings of and transactions in
securities issued by the Company (b) revocation by the undersigned in a signed
writing delivered to the foregoing attorneys-in-fact or (c) as to any
attorney-in-fact individually until such attorney-in-fact is no longer employed
by the Company or Cooley LLP.
       IN WITNESS WHEREOF the undersigned has caused this Power of Attorney to
be executed as of this 2nd day of June 2021.

/s/ Elizabeth Nabel
Elizabeth Nabel







1